Sarepta Therapeutics Stock Forecast, Price & News

Sarepta Therapeutics (NASDAQ:SRPT) Frequently Asked Questions

Is Sarepta Therapeutics a buy right now?

20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last twelve months. There are currently 9 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Sarepta Therapeutics stock.
View analyst ratings for Sarepta Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Sarepta Therapeutics?

Wall Street analysts have given Sarepta Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Sarepta Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Sarepta Therapeutics' next earnings date?

Sarepta Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Sarepta Therapeutics.

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) issued its earnings results on Wednesday, August, 4th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($1.29) by $0.27. The biotechnology company had revenue of $164.09 million for the quarter, compared to analyst estimates of $161.95 million. Sarepta Therapeutics had a negative net margin of 105.73% and a negative trailing twelve-month return on equity of 94.90%. The firm's revenue for the quarter was up 19.5% on a year-over-year basis. During the same period last year, the company earned ($1.93) earnings per share.
View Sarepta Therapeutics' earnings history.

How has Sarepta Therapeutics' stock been impacted by Coronavirus?

Sarepta Therapeutics' stock was trading at $102.8150 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SRPT shares have decreased by 11.9% and is now trading at $90.57.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for SRPT?

20 analysts have issued 1 year price objectives for Sarepta Therapeutics' stock. Their forecasts range from $75.00 to $215.00. On average, they expect Sarepta Therapeutics' stock price to reach $129.06 in the next year. This suggests a possible upside of 42.5% from the stock's current price.
View analysts' price targets for Sarepta Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Sarepta Therapeutics' key executives?

Sarepta Therapeutics' management team includes the following people:

• Douglas S. Ingram, President, Chief Executive Officer & Director
• Ian M. Estepan, Executive VP, Chief Financial & Accounting Officer
• Louise Rodino-Klapac, Chief Scientific Officer & Executive VP
• Gilmore O’Neill, Chief Medical Officer & Executive Vice President
• Dallan Murray, Chief Commercial Officer & Senior Vice President

What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO?

15 employees have rated Sarepta Therapeutics CEO Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among Sarepta Therapeutics' employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Sarepta Therapeutics' key competitors?

Some companies that are related to Sarepta Therapeutics include Genmab A/S (GMAB), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Horizon Therapeutics Public (HZNP), Catalent (CTLT), Royalty Pharma (RPRX), Alnylam Pharmaceuticals (ALNY), UCB (UCBJF), Viatris (VTRS), Elanco Animal Health (ELAN), BioMarin Pharmaceutical (BMRN), Maravai LifeSciences (MRVI), Ono Pharmaceutical (OPHLF), Zai Lab (ZLAB) and CureVac (CVAC).
View all of SRPT's competitors.

What other stocks do shareholders of Sarepta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and The Walt Disney (DIS).

What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

Who are Sarepta Therapeutics' major shareholders?

Sarepta Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.34%), Avoro Capital Advisors LLC (3.01%), JPMorgan Chase & Co. (1.64%), Geode Capital Management LLC (1.23%), First Trust Advisors LP (1.10%) and Price T Rowe Associates Inc. MD (0.90%). Company insiders that own Sarepta Therapeutics stock include Alexander Cumbo, David T Howton, Hans Lennart Rudolf Wigzell, Joseph Bratica, M Kathleen Behrens, Richard Barry and Sandesh Mahatme.
View institutional ownership trends for Sarepta Therapeutics.

Which institutional investors are selling Sarepta Therapeutics stock?

SRPT stock was sold by a variety of institutional investors in the last quarter, including Lazard Asset Management LLC, JPMorgan Chase & Co., ARK Investment Management LLC, Sumitomo Mitsui Trust Holdings Inc., Legal & General Group Plc, APG Asset Management N.V., Citadel Advisors LLC, and Swiss National Bank. Company insiders that have sold Sarepta Therapeutics company stock in the last year include Hans Lennart Rudolf Wigzell, Joseph Bratica, and M Kathleen Behrens.
View insider buying and selling activity for Sarepta Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Sarepta Therapeutics stock?

SRPT stock was acquired by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Point72 Asset Management L.P., CIBC Asset Management Inc, Avoro Capital Advisors LLC, Macquarie Group Ltd., Caas Capital Management LP, Renaissance Technologies LLC, and Marshall Wace North America L.P..
View insider buying and selling activity for Sarepta Therapeutics or or view top insider-buying stocks.

How do I buy shares of Sarepta Therapeutics?

Shares of SRPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sarepta Therapeutics' stock price today?

One share of SRPT stock can currently be purchased for approximately $90.57.

How much money does Sarepta Therapeutics make?

Sarepta Therapeutics has a market capitalization of $7.23 billion and generates $540.10 million in revenue each year. The biotechnology company earns $-554,130,000.00 in net income (profit) each year or ($7.11) on an earnings per share basis.

How many employees does Sarepta Therapeutics have?

Sarepta Therapeutics employs 866 workers across the globe.

What is Sarepta Therapeutics' official website?

The official website for Sarepta Therapeutics is www.sareptatherapeutics.com.

Where are Sarepta Therapeutics' headquarters?

Sarepta Therapeutics is headquartered at 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142.

How can I contact Sarepta Therapeutics?

Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at (857) 242-4000 or via email at [email protected].